Combination Treatment for Myelofibrosis Shows Potential in Early Trial
source: pixabay.com

Combination Treatment for Myelofibrosis Shows Potential in Early Trial

According to a story from Targeted Oncology, findings from a recent phase 1 trial have discovered a new potential treatment for myelofibrosis. The study combined two different drugs: panobinostat (marketed…

Continue Reading Combination Treatment for Myelofibrosis Shows Potential in Early Trial

Huntsman Lab Research Team Discovers that Selinexor May Benefit Myelofibrosis Patients Who have No Other Curative Options

  Myelofibrosis (MF) comes under the heading of rare cancer. A recent article in Newswise, University of Utah, describes the disease as the failure of bone marrow to produce normal…

Continue Reading Huntsman Lab Research Team Discovers that Selinexor May Benefit Myelofibrosis Patients Who have No Other Curative Options
Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
qimono / Pixabay

Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study

According to a publication from Oncology Nurse Advisor, a study of 109 patients with myeloproliferative neoplasms (certain types of blood cancers) found that mortality rates for younger patients were similar…

Continue Reading Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
First Patient Dosed in Phase 1b Trial of Experimental Myelofibrosis Drug
Source: Pixabay.com

First Patient Dosed in Phase 1b Trial of Experimental Myelofibrosis Drug

According to a press release from biotechnology company Forbius (Formation Biologics Inc.), the first patient in the Company's phase 1b trial of experimental myelofibrosis (MF) drug AVID200 has successfully received…

Continue Reading First Patient Dosed in Phase 1b Trial of Experimental Myelofibrosis Drug
Mutations are the Key to Predicting Outcomes in Myeloproliferative Neoplasms, Study Says
Katzenfee50 / Pixabay

Mutations are the Key to Predicting Outcomes in Myeloproliferative Neoplasms, Study Says

According to a story from Cure Today, a recent study has found that identifying mutations in patients with myeloproliferative neoplasms may be the key in predicting outcomes, such as disease…

Continue Reading Mutations are the Key to Predicting Outcomes in Myeloproliferative Neoplasms, Study Says
Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
stevepb / Pixabay

Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released

The drug Jakavi (ruxolitinib) is being investigated as a possible treatment for polycythemia vera (PV) and myelofibrosis. Results from studies into this were presented by Novartis at the 23rd Congress of…

Continue Reading Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
Close Menu